Abstract:Objective To evaluate the clinical efficacy and safety of rivastigmine in treatment of patients with vascular dementia (VD). Methods All 98 VD patients (MMSE score between 10 to 26) from 7 centers were randomized into two groups, the control group (n=48) took maintenane therapy for cerebral vascular disease (CVD), the rivastigmine group (n=50) took rivastigmine 4.5-6.0 mg/d, however 13 cases were dropped because of the interference of SARS, which resulted in a control group of 37 cases and a revastigmine group of 48 cases. The duration was 12 weeks. The scales of MMSE, VDAS-cog, ADL, and ADAS-noncog were used to assess the effects on cognitive function, ability of daily living, and behavior symptoms respectively at both baseline and the end of 12 weeks; general change was rated with scales of ADCS-CGIC. Safety issues, including vital signs, lab assays, and ECG examinations, were meassured every 2 or 4 weeks. Results The subjects met the definition of ITT population. Patients of the rivastigmine group got statistically significant improvement in neuropsychological tests in memory, orientation, concentration, and visual-spatial functions. In rivastigmine group, the total score of MMSE(12 weeks 20.2±4.8, baseline 18.9±4.8,P=0.003)and digit span test (12 weeks 3.5±1.5 , baseline 4.2±1.8, P=0.01) were improved than the baseline in comparison with the controlled group; no significant difference was found in ADL scale between 12 weeks and baseline in both groups (P0.05); reduction of delusion(P=0.03)and tearfulness (P=0.06) appeared in patients of the rivastigmine group. There were 65.1% patients of the rivastigmine group declared clinical improvement, more than that of the control group (40.1%). The difference of general efficacy between the two groups was nearly statistically significant (P=0.06). One severe adverse event occurred in the control group during the trial. The incidence of the control group and the rivastigmine group adverse events was 8.1% and 10.4%, respectively, showing no significant differences between groups. Rivastigmine had little influence on vital signs and lab assays. Conclusion Rivastigmine might improve the clinical symptoms of VD patients, with acceptable safety and tolerance. It should be a candidate treatment for VD.

Clinical Efficacy and Safety of Rivastigmine in Treatment of Vascular Dementia: a Multi-Center, Open-Label, Randomized, Controlled Trial